Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | AMLX |
---|---|---|
09:32 ET | 72546 | 2.94 |
09:34 ET | 31339 | 2.92 |
09:36 ET | 79065 | 2.92 |
09:38 ET | 34167 | 2.925 |
09:39 ET | 14844 | 2.88 |
09:41 ET | 11098 | 2.88 |
09:43 ET | 15805 | 2.885 |
09:45 ET | 7897 | 2.895 |
09:48 ET | 2173 | 2.871 |
09:50 ET | 37604 | 2.89 |
09:52 ET | 11167 | 2.94 |
09:54 ET | 20909 | 2.955 |
09:56 ET | 6923 | 2.9301 |
09:57 ET | 2670 | 2.945 |
09:59 ET | 17850 | 2.93 |
10:01 ET | 8301 | 2.925 |
10:03 ET | 26900 | 2.916 |
10:06 ET | 11370 | 2.92 |
10:08 ET | 22778 | 2.9211 |
10:10 ET | 1450 | 2.92 |
10:12 ET | 21934 | 2.9 |
10:14 ET | 1600 | 2.92 |
10:15 ET | 8746 | 2.935 |
10:17 ET | 2069 | 2.935 |
10:19 ET | 3336 | 2.925 |
10:21 ET | 6660 | 2.94 |
10:24 ET | 6838 | 2.965 |
10:26 ET | 18875 | 2.97 |
10:28 ET | 17454 | 2.9501 |
10:30 ET | 23299 | 2.925 |
10:32 ET | 4626 | 2.915 |
10:33 ET | 2004 | 2.915 |
10:35 ET | 4596 | 2.905 |
10:37 ET | 2794 | 2.895 |
10:39 ET | 6800 | 2.895 |
10:42 ET | 27639 | 2.9 |
10:44 ET | 3854 | 2.915 |
10:46 ET | 11665 | 2.905 |
10:48 ET | 4345 | 2.895 |
10:50 ET | 5309 | 2.895 |
10:51 ET | 200 | 2.9 |
10:53 ET | 1600 | 2.89 |
10:55 ET | 1312 | 2.89 |
10:57 ET | 3807 | 2.895 |
11:00 ET | 1200 | 2.875 |
11:02 ET | 100 | 2.875 |
11:04 ET | 1045 | 2.885 |
11:06 ET | 1998 | 2.895 |
11:08 ET | 200 | 2.8997 |
11:09 ET | 1581 | 2.9 |
11:11 ET | 9121 | 2.91 |
11:13 ET | 5196 | 2.891 |
11:15 ET | 600 | 2.9 |
11:18 ET | 1283 | 2.905 |
11:20 ET | 6762 | 2.91 |
11:22 ET | 1339 | 2.92 |
11:24 ET | 6482 | 2.924 |
11:26 ET | 2961 | 2.93 |
11:27 ET | 1891 | 2.935 |
11:29 ET | 1979 | 2.93 |
11:31 ET | 3823 | 2.9499 |
11:33 ET | 5729 | 2.9601 |
11:36 ET | 8638 | 2.96 |
11:38 ET | 19660 | 2.935 |
11:40 ET | 15971 | 2.935 |
11:42 ET | 9052 | 2.945 |
11:44 ET | 2035 | 2.945 |
11:45 ET | 3281 | 2.94 |
11:47 ET | 416 | 2.94 |
11:49 ET | 8228 | 2.955 |
11:51 ET | 2526 | 2.95 |
11:56 ET | 6594 | 2.95 |
11:58 ET | 3881 | 2.9501 |
12:02 ET | 10756 | 2.935 |
12:03 ET | 1181 | 2.9399 |
12:05 ET | 1150 | 2.9303 |
12:07 ET | 1279 | 2.925 |
12:09 ET | 2260 | 2.925 |
12:12 ET | 713 | 2.921 |
12:14 ET | 3871 | 2.92 |
12:18 ET | 1536 | 2.9199 |
12:20 ET | 500 | 2.92 |
12:21 ET | 599 | 2.915 |
12:23 ET | 800 | 2.92 |
12:25 ET | 5143 | 2.895 |
12:27 ET | 1300 | 2.895 |
12:30 ET | 1274 | 2.9 |
12:32 ET | 9232 | 2.895 |
12:34 ET | 5652 | 2.875 |
12:36 ET | 2600 | 2.88 |
12:38 ET | 344 | 2.879 |
12:39 ET | 300 | 2.88 |
12:41 ET | 100 | 2.872888 |
12:43 ET | 7210 | 2.88 |
12:45 ET | 1036 | 2.88 |
12:48 ET | 19196 | 2.905 |
12:50 ET | 740 | 2.9098 |
12:52 ET | 11117 | 2.895 |
12:54 ET | 19360 | 2.89 |
12:56 ET | 3994 | 2.89 |
12:57 ET | 2526 | 2.891 |
12:59 ET | 3100 | 2.895 |
01:01 ET | 22041 | 2.855 |
01:03 ET | 3960 | 2.86 |
01:06 ET | 900 | 2.859 |
01:08 ET | 2300 | 2.86 |
01:10 ET | 6755 | 2.86 |
01:12 ET | 5700 | 2.851 |
01:15 ET | 300 | 2.86 |
01:17 ET | 1200 | 2.855 |
01:19 ET | 5541 | 2.855 |
01:21 ET | 1564 | 2.855 |
01:24 ET | 15941 | 2.851 |
01:26 ET | 5148 | 2.8536 |
01:28 ET | 1200 | 2.8599 |
01:30 ET | 1418 | 2.869 |
01:32 ET | 2850 | 2.8667 |
01:33 ET | 1806 | 2.861 |
01:35 ET | 1893 | 2.865 |
01:39 ET | 10836 | 2.855 |
01:42 ET | 875 | 2.855 |
01:44 ET | 300 | 2.855 |
01:46 ET | 40130 | 2.885 |
01:48 ET | 2900 | 2.89 |
01:50 ET | 16039 | 2.91 |
01:51 ET | 5100 | 2.895 |
01:53 ET | 11383 | 2.93 |
01:55 ET | 3148 | 2.93 |
01:57 ET | 32083 | 2.92 |
02:00 ET | 100 | 2.925 |
02:02 ET | 1371 | 2.925 |
02:04 ET | 3674 | 2.91 |
02:06 ET | 4758 | 2.91 |
02:11 ET | 1471 | 2.915 |
02:13 ET | 400 | 2.915 |
02:15 ET | 12644 | 2.895 |
02:18 ET | 100 | 2.895 |
02:20 ET | 3271 | 2.885 |
02:22 ET | 2900 | 2.87 |
02:24 ET | 1500 | 2.8791 |
02:26 ET | 1534 | 2.875 |
02:27 ET | 4200 | 2.875 |
02:29 ET | 1290 | 2.87 |
02:31 ET | 900 | 2.87 |
02:33 ET | 2039 | 2.88 |
02:36 ET | 300 | 2.88 |
02:38 ET | 339 | 2.875 |
02:40 ET | 517 | 2.88 |
02:42 ET | 600 | 2.88 |
02:44 ET | 504 | 2.871 |
02:45 ET | 19520 | 2.885 |
02:47 ET | 5175 | 2.8797 |
02:49 ET | 9480 | 2.865 |
02:51 ET | 1146 | 2.87 |
02:54 ET | 10793 | 2.8792 |
02:56 ET | 1400 | 2.875 |
02:58 ET | 500 | 2.8792 |
03:00 ET | 3400 | 2.875 |
03:02 ET | 200 | 2.88 |
03:03 ET | 300 | 2.88 |
03:05 ET | 7990 | 2.875 |
03:07 ET | 750 | 2.875 |
03:09 ET | 100 | 2.8769 |
03:12 ET | 16131 | 2.8701 |
03:14 ET | 700 | 2.875 |
03:16 ET | 100 | 2.875 |
03:18 ET | 1200 | 2.875 |
03:20 ET | 21580 | 2.865 |
03:21 ET | 3400 | 2.865 |
03:23 ET | 2651 | 2.865 |
03:25 ET | 26898 | 2.865 |
03:30 ET | 2553 | 2.88 |
03:32 ET | 100 | 2.875 |
03:34 ET | 4934 | 2.875 |
03:36 ET | 49368 | 2.895 |
03:38 ET | 300 | 2.9 |
03:39 ET | 8475 | 2.895 |
03:41 ET | 5044 | 2.905 |
03:43 ET | 1817 | 2.8901 |
03:45 ET | 1872 | 2.885 |
03:48 ET | 500 | 2.885 |
03:50 ET | 5846 | 2.895 |
03:52 ET | 1402 | 2.8965 |
03:54 ET | 3971 | 2.895 |
03:56 ET | 16501 | 2.9 |
03:57 ET | 22400 | 2.89 |
03:59 ET | 146533 | 2.92 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Amylyx Pharmaceuticals Inc | 180.4M | -1.2x | --- |
Organogenesis Holdings Inc | 379.2M | -23.3x | --- |
Amarin Corporation PLC | 242.7M | -7.3x | --- |
Coherus BioSciences Inc | 121.0M | -2.6x | --- |
Sinovac Biotech Ltd | 639.9M | -4.9x | --- |
Ironwood Pharmaceuticals Inc | 714.0M | 103.7x | --- |
Amylyx Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery and development of treatments for neurodegenerative diseases. The Company is focused on the development and commercialization of its product candidate: AMX0035 for the treatment of Wolfram syndrome and for the treatment of progressive supranuclear palsy, and AMX0114, the Company’s antisense oligonucleotide targeting calpain-2 for the treatment of amyotrophic lateral sclerosis (ALS). AMX0035 is a dual-unfolded protein response (UPR)-Bax apoptosis inhibitor composed of PB and TURSO (also known as TUDCA). The Company’s Avexitide is an investigational, first-in-class glucagon-like peptide-1 (GLP-1) receptor antagonist that has been evaluated in five clinical trials for post-bariatric hypoglycemia (PBH) and has also been studied in congenital hyperinsulinism (HI), two indications characterized by hyperinsulinemic hypoglycemia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $180.4M |
---|---|
Revenue (TTM) | $298.8M |
Shares Outstanding | 68.1M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.45 |
Book Value | $6.40 |
P/E Ratio | -1.2x |
Price/Sales (TTM) | 0.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -59.50% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.